Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ENO1 | P06733 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | POLG | P54098 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758987 | 0.91 | BTN3A1 (0.43) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL18309146 | 0.86 | BTN3A1 (0.40) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL10128755 | 0.85 | BTN3A1 (0.47) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL18309164 | 0.85 | BTN3A1 (0.47) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL10378800 | 0.84 | BTN3A1 (0.50) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL28720185 | 0.83 | BTN3A1 (0.53) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL3437081 | 0.83 | BTN3A1 (0.53) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL10378801 | 0.83 | BTN3A1 (0.49) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL18712422 | 0.81 | ALDH1A1 (0.54) | BTN3A1ALDH1A1ENO1PRKCAFNTA | |
| SCHEMBL2458617 | 0.81 | BTN3A1 (0.60) | BTN3A1ALDH1A1ENO1PRKCAFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | NEOVIRTECH (FR) | 2021-03-18 | — | — | US | disclosed |
| EP-3738969-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES FOR USE IN TREATING PNEUMOVIRINAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20170327526-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016028866-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-8785629-B2 | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20120142897-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | UNIVERSITE D'ORLEANS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100143960-A1 | CYANINE DERIVATIVES, FLUORESCENT CONJUGATES CONTAINING SAME AND USE THEREOF | CIS BIO INTERNATIONAL (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| US-7601703-B2 | Enzyme catalyzed therapeutic agents | CELMED ONCOLOGY (USA), INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| US-7419968-B1 | Methods for treating therapy-resistant tumors | CELMED ONCOLOGY (USA), INC. (CA) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | BTN3A1 2428/4885ALDH1A1 330/4885ENO1 1420/4885 |
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | TYMP, EIF2AK2, PNP | BTN3A1 4408/4885ALDH1A1 2309/4885ENO1 1910/4885 |
| US-20120142897-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | PNP, PHPT1, TYMP | BTN3A1 3336/4885ALDH1A1 3189/4885ENO1 409/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | BTN3A1 3529/4885ALDH1A1 4266/4885ENO1 3614/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | BTN3A1 2837/4885ALDH1A1 3727/4885ENO1 2948/4885 |
| US-20170327526-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | TYMP, DPYD, TYMS | BTN3A1 4572/4885ALDH1A1 1308/4885ENO1 2732/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | BTN3A1 2837/4885ALDH1A1 3727/4885ENO1 2948/4885 |
| US-20100143960-A1 | CYANINE DERIVATIVES, FLUORESCENT CONJUGATES CONTAINING SAME AND USE THEREOF | C9, CBR3, C3AR1 | BTN3A1 865/4885ALDH1A1 3628/4885ENO1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.